Dyne Therapeutics

Dyne Therapeutics develops therapeutics aimed at improving the functional outcomes for individuals with genetically driven neuromuscular diseases. By focusing on muscle and central nervous system interventions, the company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), along with preclinical initiatives for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.